SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback